SHEN26
CAS No. 2647441-36-7
SHEN26( —— )
Catalog No. M28490 CAS No. 2647441-36-7
SHEN26 has antiviral activity and can be used in research on the treatment of viral infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 222 | Get Quote |
|
| 10MG | 357 | Get Quote |
|
| 25MG | 597 | Get Quote |
|
| 50MG | 851 | Get Quote |
|
| 100MG | 1152 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSHEN26
-
NoteResearch use only, not for human use.
-
Brief DescriptionSHEN26 has antiviral activity and can be used in research on the treatment of viral infections.
-
DescriptionSHEN26 has antiviral activity and can be used in research on the treatment of viral infections.
-
In VitroObeldesivir (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. Obeldesivir has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC50 values of 0.349 μM and 0.106 μM, respectively.
-
In VivoObeldesivir (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (Cmax) of 8.2 μM.Obeldesivir (250-500 mg/kg; p.o.; daily, for 4 days; hACE2 knock-in and Ad5-hACE2 mice) has antiviral activity and inhibits SARS-CoV-2 replication in mouse models.Obeldesivir (100-250 mg/kg; p.o.; daily, for 10 days) reduces lung damage and protects K18-hACE2 mice.Obeldesivir (10-150 mg/kg; p.o.; daily, for 3 days) reduces virus titers and lung damage caused by Delta variant infection in K18-hACE2 mice. Animal Model:hACE2 knock-in and Ad5-hACE2 mice Dosage:250 and 500 mg/kg Administration:Oral administration; daily, for 4 days Result:Inhibited gRNA and sgRNA, which is Biomarkers of coronavirus replication. Reduced the viral load and pathological damage of the lung.Animal Model:K18-hACE2 mice Dosage:100 and 250 mg/kg Administration:Oral administration; daily, for 10 days Result:Reduced viral RNA and increased the survival rate of mice. Reduced evidence of lung pathology and the production of inflammatory cytokines and chemokines in the lung tissues.Animal Model:K18-hACE2 mice Dosage:10, 30, 80 and 150 mg/kg Administration:Oral administration; daily, for 3 days Result:Reduced viral load in a dose-dependent manner and alleviated the symptoms in the lung.
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
RecptormTOR| PI3Kα/PI3Kγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2647441-36-7
-
Formula Weight361.35
-
Molecular FormulaC16H19N5O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (691.85 mM)
-
SMILESN#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@H](COC(C(C)C)=O)[C@@H](O)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SARS-CoV-2 nsp13-IN-...
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent inhibitor of nsp13 (non-structural protein 13), selectively inhibiting nsp13 ssDNA+ATPase with an IC50 of 6 μM, but not ssDNA-ATPase, and can be used to study COVID-19.
-
(R,1R)-Tenofovir ami...
(R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) is an orally administered Tenofovir prodrug with antiviral activity. Tenofovir is a nucleotide reverse transcriptase inhibitor.
-
ITMN4077
ITMN4077 has antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication with an EC50 of 2.131μM.
Cart
sales@molnova.com